Geneos Wealth Management Inc. Raises Stake in Danaher Co. (NYSE:DHR)

Geneos Wealth Management Inc. lifted its position in Danaher Co. (NYSE:DHR) by 2.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,713 shares of the conglomerate’s stock after purchasing an additional 399 shares during the period. Geneos Wealth Management Inc.’s holdings in Danaher were worth $3,837,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the company. FMR LLC raised its holdings in Danaher by 15.8% during the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after acquiring an additional 3,217,631 shares during the period. Massachusetts Financial Services Co. MA raised its stake in Danaher by 17.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after purchasing an additional 535,254 shares during the period. International Assets Investment Management LLC lifted its holdings in Danaher by 40,196.5% in the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock worth $119,539,000 after purchasing an additional 428,897 shares in the last quarter. Montrusco Bolton Investments Inc. boosted its stake in Danaher by 30.4% in the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock worth $465,617,000 after purchasing an additional 397,671 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec grew its holdings in Danaher by 82.4% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 653,375 shares of the conglomerate’s stock valued at $181,651,000 after buying an additional 295,187 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Trading Up 0.1 %

NYSE DHR opened at $245.95 on Friday. Danaher Co. has a 12 month low of $225.42 and a 12 month high of $281.70. The company’s 50-day moving average price is $235.33 and its 200-day moving average price is $253.45. The stock has a market cap of $177.65 billion, a PE ratio of 46.94, a PEG ratio of 4.43 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Analyst Ratings Changes

A number of brokerages recently weighed in on DHR. UBS Group dropped their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Scotiabank began coverage on Danaher in a report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price on the stock. Stephens reissued an “overweight” rating and set a $315.00 price target on shares of Danaher in a research note on Wednesday, October 23rd. TD Cowen lifted their price objective on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Finally, StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $285.55.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.